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Background: The prevalence of monoclonal gammopathy of undetermined significance (MGUS), a premalignant
plasma-cell disorder has not been determined in our geographic area Nigeria.
Methods: A cross sectional survey was carried on apparently healthy Nigerians selected by multistage sampling
technique from the cosmopolitan city of Lagos, Nigeria. Subjects enrolled into the study had 2-step screening for
the presence, type and concentration of monoclonal band. Agarose-gel electrophoresis was performed on all
serum samples, and any serum sample with a discrete band of monoclonal protein or thought to have a localized
band was subjected to Immunofixation. Subjects were also evaluated for Bence jones proteinuria, haematological
and biochemical parameters.
Results: Four hundred and ten subjects with a mean age of 45.68 ± 10.3 years, a median of 45.00 years and a range
of 20 to 80 years were enrolled into the study. MGUS was identified in only one (0.24 percent) of the 410 study
subject. This subject was demonstrated to have a double monoclonal gammopathy; IgGλ at 16.9 g/L and IgAκ at
8.5 g/L. None of them including the sole subject with MGUS had a monoclonal urinary light chain.
Conclusion: Among residents of Lagos, Nigeria, MGUS was found in only 0.24% percent of apparently normal
persons with a median age of 45 years. This suggests that MGUS which represents the earliest stage of monoclonal
plasma/lymphoid cell proliferation is not a common finding in the relatively young population of Nigeria. Future
epidemiologic studies dealing with plasma cell disorders in older people are required to carefully examine the
relationship between environmental factors and prevalence of MGUS and its ultimate progression to MM.
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Monoclonal Gammopathy of Undetermined Significance
(MGUS) is the most common of a spectrum of diseases
called plasma cell dyscrasias [1,2], which are a heteroge-
neous group of diseases characterized by the expansion
of a clone of bone marrow plasma cells that produce
monoclonal immunoglobulin (Ig).* Correspondence: titilopeadeyemo2002@yahoo.co.uk
2Department of Haematology & Blood Transfusion, Faculty of Clinical
Sciences, College of Medicine, University of Lagos, P.M.B. 12003, Marina,
Lagos, Nigeria
Full list of author information is available at the end of the article
© 2012 Onwah et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe term Monoclonal gammopathy of undetermined
significance (MGUS) denotes the presence of a mono-
clonal protein (M-Protein) in plasma or urine without
evidence of multiple myeloma (MM), Waldenström’s
macroglobulinaemia (WM), amyloidosis, or B cell
related disorders [3]. It has two important characteris-
tics; the first is a plasma immunoglobulin or serum M
protein concentration of less than 3 g/dl, only small or
no urinary immunoglobulin light chain (Bence jones
proteinuria) that has molecular features of the product
of a single clone of B lymphocytes or plasma cells and
the second is the absence of evidence of an overt neo-
plastic disorder of B lymphocyte or plasma cells such asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Onwah et al. BMC Blood Disorders 2012, 12:7 Page 2 of 6
http://www.biomedcentral.com/1471-2326/12/7lymphoma or multiple myeloma i.e. less than 10% of
plasma cells in bone marrow, no anemia, no osteolytic
lesions, no hypercalcemia, and no renal dysfunction and
most importantly, stability of the M-protein [4].
This condition is also referred to as Essential Mono-
clonal Gammopathy and Benign Monoclonal Gammopa-
thy but the term Monoclonal Gammopathy of
Undetermined Significance (MGUS) remains the pre-
ferred designation because of the recognition that this
disorder can evolve into a Malignant Monoclonal Gam-
mopathy. While the M- protein may remain stable and
benign, it can however progresses to symptomatic MM,
Waldenström macroglobulinaemia, light-chain (AL)
amyloidosis or a B-cell lymphoma over years of observa-
tion in about one-third of patients [5]. Longitudinal
follow-up studies have shown that most person with
MGUS do not require specific treatment and have a long
life span, the subset that evolves to the B cell lympho-
proliferative disease will require follow up monitoring
and treatment. Because the benign nature of an MGUS
is sometimes difficult to ascertain, repeated examina-
tions of the person over long periods are required.
The prevalence of MGUS is reported to vary from 1%
to 10% in different series, and the frequency is also
reported to increase with age [6-12]. It is a relatively
common condition among individuals older than
70 years, occurring in 1 percent of the population older
than 50 years, 3 percent in those older than 70 years,
and 10 percent in those over 80 years of age. While
international frequencies are nearly the same; the preva-
lence of MGUS has rarely been reported from Africa.
Though it seems important to identify early factors
that might predict a malignant transformation in people
with MGUS, determining the prevalence of MGUS is
undoubtedly a starting point and if there are large num-
ber of persons with monoclonal antibody of undefined
significance in a given population, it might be an indica-
tor of how prevalent associated B-cell malignancy is in
the given population. This study therefore aims to deter-
mine the prevalence and type of MGUS in an apparently
healthy population of Nigerians.
Methods
This was a cross-sectional study of apparently healthy
adult volunteers. Ethical clearance was obtained from
the Lagos University Teaching Hospital Health Research
and Ethics Committee (HREC) that approved the study
protocol and informed consent documents with refer-
ence number; REF.NO. ADM/DCST/HREC/VOL.11/
221. Four hundred and fourteen apparently healthy Ni-
gerian adult volunteers without a known liver disease,
lymphoproliferative disease, HIV/AIDS, on any immuno-
suppressant, or organ transplantation were enrolled into
the study. Subjects were selected using stratified randomsampling of household, with strata defined as the con-
stituent counties or other geographic subdivisions of
Lagos, a metropolis. Prospective participants were
approached face to face by a trained recruitment coord-
inator and enrolled once they consent and meet the
study enrollment criteria. Not more than one participant
was enrolled per household.
A minimum sample size of 386 participants was deter-
mined by using the statistical formula of Fisher for cal-
culating sample size N=Z2pq/d2 when the study
population is greater than 10,000 [13]. Standard devi-
ation was set at 1.96 which corresponds to the 95% con-
fidence interval and the proportion in the target
population (p) estimated to have MGUS was set at a rea-
sonable estimate of 0.5 (50% - maximum proportion to
give the largest minimum sample size). This reasonable
estimate was chosen based on the fact that the preva-
lence of MGUS is yet to be determined for the study
population [13]. Degree of accuracy was set at 0.05.
A written informed consent was obtained from each
subject and blood sample was taken for the evaluation of
hemoglobin concentration, white cell, lymphocyte and
platelet count, serum albumin, quantification of total
serum protein and albumin, serum creatinine, alkaline
phosphatase, presence, size and type of a serum Mono-
clonal Component, and erythrocyte sedimentation rate
(ESR). Urine was also collected for evaluation of the
presence of urine monoclonal protein.
Hemogram was carried out on EDTA anticoagulated
blood using the sysmex KX 21 N Haematology analyzer.
Erythrocyte sedimentation rates in mm/hr were deter-
mined manually by the Westergren method. Serum
chemistry: Total serum proteins, Serum albumin, serum
globulin and serum creatinine were determined by auto-
mation. Serum protein electrophoresis (SPEP) was car-
ried out on the subjects using a commercial kit: the
Hydragel Protein (E) K20, manufactured by Sebia Inc,
Norcross, Ga, USA and designed for seperation of
human serum proteins into six major fractions on alka-
line buffered (pH 8.5) agarose gel. The M-protein was
identified visually as a localized band on the agarose gel
electrophoretic strip and as a tall, narrow spike or peak
in the β or γ region or rarely, in the α2 - globulin area of
a densitometer tracing.
Subject identified with a monoclonal band on serum
electrophoresis was recalled for evaluation of possible
risk factors including family history of MGUS or mye-
loma, occupational chemical exposure and for screening
for urinary Bence -Jones protein by the Bradshaw’s test
for Bence -Jones protein76 and a bone marrow aspiration
to determine the percentage bone marrow plasma cell
after obtaining an informed consent. He also had Serum
Immunofixation to type and determine the concentra-
tion of the monoclonal protein. Serum immunofixation
Figure 1 Serum protein electrophoretic patterns on an Agarose
gel showing subject’s β band appearing dense and a discrete
band in the γ region. This is shown with the arrows.
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by a technique that combines zone electrophoresis with
immunoprecipitation.
Data were analyzed using statistical software package:
SPSS for windows (version 15; SPSS Inc, Chicago, IL)
and Microsoft excel. Results are presented in simple pro-
portions using tables. Comparisons of mean values
where applicable, involved the use of student t- test.
Discrete variables were compared using chi-square test.
The critical level of significance was set at p < 0.05.
Results
A total of 414 participants were enrolled into the study
with a mean age of 45.68 ± 10.3 years, a median of
45.00 years and a range of 20 to 84 years. There were
126 (30.4%) females and 288 (69.6%) males with no stat-
istical difference in the mean age of the females
(46.33 ± 13 years) with a median age of 47.5 years and
that of the males with a mean of 45.39 ± 8.9 years and a
median of age of 44 years (P= 0.39), (Table 1). While
44.4% of the sample population was in the age range 40-
49 years, only 34% were above 50 years and 1.22% was
above 70 years.
Four hundred and ten of the 414 subjects enrolled in
the study had serum protein electrophoresis (SPEP)
done because 4 samples were hemolyzed or insufficient
and unsuitable for electrophoretic analysis. Only one of
the 410 subjects who had sera subjected to Agarose gel
SPEP had the β band appearing dense and a discrete
band in the γ region. (Figure 1), Thus only 0.24 percent
of the sample population has a monoclonal gammopa-
thy. Figures 2a and 2b shows the densitometry scan of
gel of a normal serum and subject with discrete band in
the γ region.
Characteristics of the only study subject with a
monoclonal band
The sole subject found with a monoclonal band in this
study was an apparently healthy 40-year old male,Table 1 Frequency and mean ages of subjects
Sex Frequency (%) Mean age (yrs) Median age (yrs)
Males 288 (69.6) 45.39± 8.93 44
Females 126 (30.4) 46.33 ± 12.95 47.5
total 414 (100) 45.68± 10.3 45
Age (year) Frequency Percent
20 -29 24 5.8
30 – 39 65 15.7
40 – 49 184 44.4
50 – 59 104 25.1
≥ 60 37 8.93
Total 414 100businessman with no family history or occupational risk
factor. He had a normal haematological and biochemical
profile. ESR was normal at 5 mm/hr. Total serum pro-
tein was elevated at 89.27 g/L (range 60-85 g/L) and al-
bumin was normal at 54.67 g/L (range 35-55 g/L) and
an A/G ratio of 1.58 (range 1.0-2.1). The beta and
gamma fractions were increased. Serum Immunofixation
showed two monoclonal peaks IgGλ in mid-γ region and
IgAk in the β region (Figure 3) with IgG concentration
of 16.9 g/l. (Normal range 7.00-16.00 g/L) and IgA of
8.5 g/l. (Normal range 0.70-3.50 g/L). His IgM level was
quantified as normal at 0.79 g/l (Normal 0.50-2.50 g/L).
Urine was negative for Urinary light chain (Bence jones
protein by Bradshaw test.
Discussion
Monoclonal gammopathy of undetermined significance
(MGUS) is one of the most common premalignant dis-
orders in Western countries. Interestingly, prevalence
and incidence patterns for MGUS and MM show strik-
ing disparity patterns across ethnic/racial groups, most
notably the two- to threefold increase in both these dis-
orders in African Americans compared with Caucasians.
In contrast, studies on Asian patients show lower preva-
lence/incidence for MGUS compared with Caucasians.
The prevalence of MGUS is reported to vary from 1%
to 10% in different series [6-12]. It occurs in 1 percent
of the population older than 50 years and, about 3 per-
cent of the population older than 70 years, and 10
Figure 2 a: Densitometry tracing of gel electrophoresis of normal serum. b: Densitometric tracing of gel electrophoresis of subject with
monoclonal band.
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based study involving 21,463 predominantly white resi-
dents of a county in Minnesota, USA, the prevalence of
MGUS was 3.2% in persons older than 50 years of age,
5.3% in persons 70 years of age or older, and almost 9%
in men older than 85 years of age [6]. In Sweden and
France, approximately 3% of persons older than 70 years
were found to have an MGUS [14]. The median age at
diagnosis of MGUS is generally about 70 years, and less
than 2% of people that have been documented to have
MGUS are younger than 40 years of age [1]. In the Min-
nesota study [6], the prevalence of MGUS was found to
be higher in men than in women, 4.0% vs. 2.7% among
persons that are 50 years or older. This finding has been
supported by several other authors [6-12].
The incidence of MGUS has also been reported to be
higher in blacks than in Whites [8-10,12]. Cohen et al. [8]
reported a prevalence of 8.4% in blacks compared with3.6% in whites while another retrospective study revealed
that the age-adjusted prevalence ratio of MGUS in African
American subjects was 3.0 compared with Caucasians
[15]. Landgren et al. [10] in their study in Ghanaian men
to test for evidence to support an underlying race-related
predisposition of a 2-fold higher prevalence of MGUS in
African Americans vs. whites found that, compared with
white men, the age-adjusted prevalence of MGUS was
1.97 - fold (95% CI, 1.94 - 2.00) higher in Ghanaian men.
They concluded that the 2 fold higher prevalence of
MGUS in Ghanaian men supports the hypothesis that
race-related genetic susceptibility results in the higher
rates of MGUS in black populations.
A prevalence of monoclonal gammopathy of 0.24% was
found in this study. This contrast the study by Landgren
et al. [10] who reported a prevalence of 5.84% of 917 male
subjects in the study in Ghanaian men. A possible explan-
ation for this discrepancy is that the subjects in the
Figure 3 Serum immunofixation electrophoresis of subject
shows two monoclonal bands: IgA kappa (in β2 position) and
IgG lambda (in mid-γ region).
Onwah et al. BMC Blood Disorders 2012, 12:7 Page 5 of 6
http://www.biomedcentral.com/1471-2326/12/7Ghanaian study were older, with an age range of 50-
74 years while in this study, the age ranged 20-84 years
with a mean of 45.68 ± 10.3 years. The prevalence of
MGUS have been clearly reported to increase with age
[6-10]. This figure also contrast the result of Iwanaga et al
[11]. from a large study in Nagasaki, Japan who found an
overall prevalence of 2.1% in 52,802 survivors of the
atomic explosion screened, 1% in participants aged 42-
49 years, 1.9% in those 50-59 yrs, 2.6% in those 60-69 yrs,
3% in those 70-79 years and 4.4% in those 80 years and
older. Though radiation exposure has been postulated to
be a possible predisposing factor for monoclonal gammo-
pathy of undetermined significance (MGUS), the associ-
ation has remained uncertain.
It is pertinent to note that subject’s age group 40-
49 years constituted the largest age group in our study
(44% or 184 of 410 subjects). Only 5 (1.22%) of the sub-
jects were aged 70 years and above and only one of 410
(0.24%) subject had a monoclonal gammopathy and was
aged 40 years. The low prevalence rate found in this
study when compared with several other studies in black
population may also (in addition to relatively younger
age of our subjects) be partly due to a smaller sample
population size.
The cause of MGUS is not known but certain genetic
and environmental exposures are postulated to be risk
factors for MGUS. In a report of atomic bomb survivors
by Iwanaga et al. [16], those exposed to high levels of ra-
diation at a young age had an increased risk of MGUS.
Specific insecticides, pesticides, and fungicides have also
been implicated inconclusively in the pathogenesis of
MGUS [17]. There is also a genetic element. A study
that examined whether monoclonal gammopathy of un-
determined significance (MGUS) is increased in first-degree relatives of multiple myeloma (MM) or MGUS
patients report that there was an increased risk of
MGUS in first-degree relatives (age-adjusted risk ratio
[RR], 2.6; 95% CI, 1.9 to 3.4) compared with the refer-
ence population [18]. The increased risk seen among
relatives of MM (RR, 2.0; 95% CI, 1.4 to 2.8) and MGUS
probands (RR, 3.3; 95% CI, 2.1 to 4.8) implies shared en-
vironment and/or genetics.
Although MGUS was initially considered a "benign"
monoclonal gammopathy, the recognition that this dis-
order can evolve into a malignant monoclonal gammo-
pathy has led to the use of the more appropriate term
"monoclonal gammopathy of undetermined significance.
It has recently been demonstrated that virtually all
patients with multiple myeloma have a preceding MGUS
[19,20]. Landgren et al. [19] showed that in 71 indivi-
duals who developed multiple myeloma during a study
and in whom serially collected serum samples were
obtained from 2 years to 9.8 years prior to the diagnosis
of the myeloma. MGUS was present in 100% of patients
2 years prior to the diagnosis of multiple myeloma. At
5 years prior to the diagnosis of multiple myeloma, 95%
had MGUS while at 8 or more years prior to the diagno-
sis of multiple myeloma, 82.4% had a preceding MGUS.
The median age of these 71 patients was 70 years and
71.4% were male. The median size of the M protein
increased from 0.9 g/dL at 8+ years to 1.6 g/dL at 2 years
prior to the diagnosis of multiple myeloma. Approxi-
mately one-half of the myeloma patients had a year-by-
year increase in M protein until the diagnosis of multiple
myeloma. The type of M protein was IgG (68%), IgA
(21.5%), IgM (1.5%), or biclonal (3%), and 4.7% had light
chain MGUS. Thus, the study established that virtually
all patients with multiple myeloma had a preceding
MGUS, a finding that was confirmed by another study
in which 27 of 30 patients with multiple myeloma had a
preceding monoclonal protein [20]. Kristinsson and col-
leagues [21] found a shorter survival in MGUS patients
when compared to the age- and sex-matched normal
population. In their report of 241 patients with MGUS,
the median survival was 13.7 years, compared to
15.5 years for the USA population.
This study has sought to determine the prevalence rate of
MGUS in our population. There is a need for future studies
to understand the epidemiology, aetio-biology and identify
potential risk factors for MGUS and factors responsible for
the progression of MGUS to a serious plasma cell dyscrasia
like myeloma in the Nigerian population.
Conclusion
Among residents of Lagos, Nigeria, MGUS was found in
0.24% percent of apparently normal persons with a me-
dian age of 45 years. There is clear evidence from this
data that the prevalence of MGUS which represents the
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eration in Nigerians is low and suggests that MGUS is
not a common finding in our relatively young popula-
tion. Future epidemiologic studies dealing with plasma
cell disorders in older people are required to carefully
examine the relationship between race, environmental
factors and prevalence of MGUS and its ultimate pro-
gression to MM. A limitation of this study is that the
numbers of participants were relatively small as reflected
in the observed prevalence of 0.24% (95% CI, 0.01-1.38).
Limited funds did not allow a larger sample size.
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